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Simvastatin Prevents and Reverses Depigmentation in
a Mouse Model of Vitiligo
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Hamidreza Pazoki-Toroudi3, Christopher A. Hunter4 and John E. Harris1
Vitiligo is a common autoimmune disease of the skin that results in disfiguring white spots. There are no Food
and Drug Administration (FDA)-approved treatments, and current treatments are time-consuming, expensive, and
of low efficacy. We sought to identify new treatments for vitiligo, and first considered repurposed medications
because of the availability of safety data and expedited regulatory approval. We previously reported that the IFN-
g-induced chemokine CXCL10 is expressed in lesional skin from vitiligo patients, and that it is critical for the
progression and maintenance of depigmentation in our mouse model of vitiligo. We hypothesized that targeting
IFN-g signaling might be an effective new treatment strategy. Activation of signal transducer and activator of
transcription 1 (STAT1) is required for IFN-g signaling and recent studies revealed that simvastatin, an FDA-
approved cholesterol-lowering medication, inhibited STAT1 activation in vitro. Therefore, we hypothesized that
simvastatin may be an effective treatment for vitiligo. We found that simvastatin both prevented and reversed
depigmentation in our mouse model of vitiligo, and reduced the number of infiltrating autoreactive CD8þ T cells
in the skin. Treatment of melanocyte-specific, CD8þ T cells in vitro decreased proliferation and IFN-g production,
suggesting additional effects of simvastatin directly on T cells. Based on these data, simvastatin may be a safe,
targeted treatment option for patients with vitiligo.
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INTRODUCTION
Vitiligo is a common, disfiguring autoimmune disease of the
skin. Psychological consequences are severe, leading to
depression, anxiety, sleep disturbances, sexual dysfunction,
feelings of discrimination, and even suicidal thoughts/attempts.
These emotional disturbances are comparable to those suffer-
ing from psoriasis and eczema (Ongenae et al., 2006; Linthorst
Homan et al., 2009). The estimated prevalence of disease is
0.5–1% of the total population (Alikhan et al., 2011), or 1.5–3
million people in the United States and 35–70 million in the
world. The estimated direct health-care cost burden of vitiligo
in the United States is $175 million each year (Bickers et al.,
2006), a particularly high cost considering that there are few
effective, and no systemic, treatments. The mechanisms of
current treatments are untested and therefore unknown,
although general, nontargeted immunosuppression is likely,
and no treatments are effective for all patients. An orally
available systemic treatment for vitiligo would be a helpful
addition to currently limited treatment options.
Vitiligo pathogenesis incorporates both intrinsic defects
within melanocytes that activate the cellular stress response
and autoimmune mechanisms that target these cells
(Schallreuter et al., 2008; Alikhan et al., 2011; Glassman,
2011; van den Boorn et al., 2011; Mosenson et al., 2012;
Passeron and Ortonne, 2012; Spritz, 2012; Toosi et al., 2012;
Laddha et al., 2013; Mosenson et al., 2013; Shah and Sinha,
2013). Patients with vitiligo have increased numbers of
autoreactive, melanocyte-specific CD8þ T cells in the skin
and blood, and functional studies using human skin ex vivo
support CD8þ T cells as critical for depigmentation (Ogg
et al., 1998; van den Boorn et al., 2009). Recent advances in
understanding the key cytokines that promote psoriasis and
related autoimmune diseases have resulted in treatments with
excellent efficacy and safety profiles, significantly improving
patients’ quality of life (Baker et al., 2012). However, the
cytokines that drive vitiligo pathogenesis are not shared with
these diseases (Rashighi et al., 2014), and cytokine-targeted
treatments for psoriasis have been ineffective for vitiligo
(Alghamdi et al., 2011, 2012; Dayel and Alghamdi, 2013).
We recently discovered that the IFN-g-chemokine axis is
active in human vitiligo, and functional studies in a vitiligo
mouse model that we developed revealed that it is critical for
both progression and maintenance of vitiligo, implicating this
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pathway as a potential target for new treatments (Harris et al.,
2012; Rashighi et al., 2014). IFN-g signaling requires the
activation of signal transducer and activator of transcription
1 (STAT1) to induce the transcription of downstream gene
targets (Aaronson and Horvath, 2002), and humans deficient
in STAT1 have severely impaired IFN-driven responses
(Dupuis et al., 2001, 2003; Chapgier et al., 2006a, b). Mice
with selective STAT1 deficiency have impaired IFN-induced
signaling and target gene expression (Meraz et al., 1996),
although some IFN-induced genes may be STAT1 -inde-
pendent (Ramana et al., 2001). We reasoned that inhibitors
of STAT1 activation might also interfere with IFN-g signaling,
and may prove to be effective treatments for vitiligo.
A recent study reported that simvastatin, an HMG-CoA
(3-hydroxy-3-methylglutaryl-coenzyme A) reductase inhibitor
approved by the Food and Drug Administration (FDA) for the
treatment of hypercholesterolemia, inhibited IFN-g-induced
STAT1 activation in vitro. This effect was specific for the
HMG-CoA reductase pathway rather than an off-target effect,
as it was rescued by the addition of mevalonate, a pathway
intermediate downstream of HMG-CoA reductase but up-
stream of cholesterol (Zhao et al., 2011). Interestingly, high-
dose simvastatin treatment of a patient with both vitiligo and
hypercholesterolemia resulted in rapid repigmentation of his
skin, supporting simvastatin treatment as a potential therapy for
vitiligo (Noel et al., 2004). Therefore, we tested simvastatin as
a treatment in our mouse model of vitiligo. We found that
simvastatin both prevented vitiligo and reversed depigmen-
tation in mice with established, widespread disease. It had
multiple effects on melanocyte-specific T cells, not only
reducing their numbers in the skin, but also reducing their
proliferation and production of IFN-g, suggesting that multiple
pleiotropic effects of simvastatin may contribute to its positive
therapeutic response.
RESULTS
Simvastatin treatment reduces the extent of depigmentation in
vitiligo
In order to test simvastatin as a potential treatment for vitiligo,
we induced vitiligo in mice with black skin and black hair as
described previously (Harris et al., 2012). Briefly, KRT14-
Kitl*4XTG2Bjl (Krt14-Kitl*) mice express a noncleavable,
membrane-bound form of Kit ligand under the keratin 14
promoter, and therefore expression is limited to the epidermis.
As a consequence, these mice have black skin and black hair,
without other sequelae (Kunisada et al., 1998). Sublethally
irradiated (500 rad) Krt14-Kitl* mice were used as hosts
for the adoptive transfer of premelanosome protein (PMEL)-
specific TCR-transgenic CD8þ T cells (PMELs) that recognize
both mouse and human PMEL (also known as gp100), a
melanocyte-specific differentiation antigen (Overwijk et al.,
1998). PMELs were isolated from the spleen of donors,
column-purified using negative selection, and 106 cells were
transferred to hosts intravenously. Mice were then infected
intraperitoneally (i.p.) with 106 plaque-forming units of recom-
binant vaccinia virus that expresses human PMEL (rVV-
hPMEL), a potent antigenic stimulus for PMELs that results in
their activation and expansion in vivo (Overwijk et al., 2003).
We have found that this treatment results in depigmentation of
the skin 5–7 weeks later, and mice are assigned a Vitiligo
Score based on the extent of depigmentation on their ears,
nose, feet, and tail (Harris et al., 2012).
To identify the optimal treatment dose of simvastatin we
performed a dose response in our model, testing three
increasing doses (0.2, 0.4, and 0.8 mg), with the highest dose
consistent with treatment in a mouse model of rheumatoid
arthritis (Leung et al., 2003). Beginning 1 day after vitiligo
induction, we began treatment of hosts with simvastatin (i.p.
3 weekly) or vehicle control until scoring them 5 weeks
later. We found that simvastatin treatment reduced depig-
mentation compared with vehicle-treated controls. There was
a strong correlation between the dose and clinical response,
with 0.8 mg having the most significant response (Figure 1a).
Flow cytometry analysis revealed a similar correlation
between the dose and the reduction of total number of PMELs
present in the ear skin (Figure 1b), and we selected 0.8 mg as
the optimal dose for repeat experiments (Figure 2a and b).
Next, we analyzed the ear skin, tail skin, skin-draining
lymph nodes, spleen, and blood by flow cytometry to quantify
the total number of PMELs present at those locations in
No
 Tx
Lo
w d
os
e 
Me
d d
os
e 
Hig
h d
ose
 
0
5
10
15
a b
Vi
tli
go
 s
co
re
P=0.004
****
No
 Tx
Lo
w d
os
e
Me
d d
os
e
Hig
h d
ose
0
1,000
2,000
3,000
4,000
5,000
N
o.
 o
f P
M
EL
/1
05
CD
45
+
 
ce
lls
P=0.0016
*** ***
No
 Tx
Lo
w d
os
e
Me
d d
os
e
Hig
h d
ose
0
10,000
20,000
30,000
N
o.
 o
f P
M
EL
/1
05
CD
45
+
 
ce
lls
NS
Ear LN
Figure 1. Simvastatin dose correlates with clinical response and reduction of melanocyte-specific CD8þ T cells in the ear skin. Vitiligo was induced and mice
were treated with 0.2, 0.4, or 0.8 mg of simvastatin or vehicle control (No Tx) three times weekly for 5 weeks. (a) There is a strong correlation between the
simvastatin dose and clinical response, with 0.8 mg having the most significant effect. P-value calculated by analysis of variance (ANOVA) is shown. Post test for
linear trend was also significant (P¼0.0014). Med, medium. (b) A similar correlation was found between simvastatin dose and reduction of melanocyte-specific
CD8þT cells (PMELs) in the ear skin, but not skin-draining lymph nodes (LNs). P-value calculated by ANOVA is shown. Post test for linear trend was also
significant (P¼ 0.0003). NS, not significant; *Po0.05; **Po0.01; and ***Po0.001.
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simvastatin-treated versus vehicle-treated controls. We found
significantly reduced numbers of PMELs in the skin in simvas-
tatin-treated hosts compared with controls, but no change in
the number of PMELs at other sites (Figure 2c and d). These
observations are consistent with our previous studies blocking
IFN-g in this model (Harris et al., 2012), and suggest that
simvastatin could be interfering with IFN-g signaling.
Acute treatment with simvastatin reduces autoreactive T cells in
the skin, but does not affect CXCL10 expression
Long-term, preventative treatment with simvastatin as above
could affect PMELs in multiple ways, including reducing the
activation or proliferation of PMELs early during priming,
migration of PMELs into the skin, or altering their function
after their recruitment to the skin. In order to determine
whether simvastatin affects T cells directly within the skin,
we induced vitiligo in hosts as before and allowed them to
develop depigmentation for 5 weeks. Next, we treated the
hosts with 1 dose of simvastatin, 3 daily doses of simvastatin,
or vehicle control and analyzed the numbers of PMELs within
the skin by flow cytometry. We found that three doses of
simvastatin significantly reduced the number of PMELs within
the ear epidermis, and even a single dose suggested a trend
toward reduction, but PMEL numbers at other sites were not
affected, including the dermis (Figure 3a and b). Antibody
neutralization of IFN-g had a similar effect (Figure 3c). These
results suggest that simvastatin acutely affects PMEL homing or
retention directly within the skin, and may inhibit IFN-g
signaling.
Our previous observations revealed that IFN-g is required
for PMEL migration to the skin and progression of disease, as
well as the maintenance of depigmentation. In addition, it
appeared that IFN-g-induced CXCL10 may specifically promote
PMEL migration within the skin to the epidermis (Rashighi et al.,
2014). In order to determine whether CXCL10 expression
is directly inhibited by simvastatin, we analyzed CXCL10
expression in the skin by reverse transcriptase–PCR (RT-PCR)
in mice treated with vehicle, one dose of simvastatin, or three
daily doses of simvastatin. We found that despite a reduction
of PMELs in the epidermis following treatment with simvasta-
tin, CXCL10 expression was unchanged (Figure 3d).
Simvastatin reduces T-cell proliferation and effector function
in vitro
Because simvastatin did not affect CXCL10 expression in the
skin, we tested whether it altered the activation or effector
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Figure 2. Simvastatin prevents depigmentation and melanocyte-specific CD8þ T-cell accumulation in the skin despite no global effect on T-cell frequency.
Vitiligo was induced and mice were treated with simvastatin (0.8mg) or vehicle control three times weekly for 5 weeks. (a) Representative mouse ears, noses,
footpads, and tails from each group are shown. (b) The effects of simvastatin on vitiligo score and (c) the total numbers of melanocyte-specific CD8þ T cells
(PMELs) in the ear skin, tail skin, lymph nodes (LNs), spleen and blood. NS, not significant. (d) Representative flow cytometry plots are shown.
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function of T cells directly. PMELs were isolated from the
spleen of donors and column-purified for CD8 T cells using
negative selection. In order to track proliferation after activa-
tion, purified PMELs were labeled with carboxyfluorescein
succinimidyl ester (CFSE). PMELs were then activated for 3
days in vitro using anti-CD3 and anti-CD8 antibodies, and
treated with either 1, 5, 10, or 100mM simvastatin or vehicle
control. We found that treatment with simvastatin reduced
both the proliferation and IFN-g production by PMELs
(Figure 4a and b), suggesting that simvastatin may directly
affect T-cell function in vitiligo, rather than indirectly by
decreasing CXCL10.
We next determined whether these direct effects of simvas-
tatin on T cells were through inhibition of the HMG-CoA
reductase pathway or through an off-target effect. HMG-CoA
reductase catalyzes the formation of mevalonate, an inter-
mediate in the cholesterol synthesis pathway (Zhao et al.,
2011). In order to test whether mevalonate supplementation
could rescue proliferation and IFN-g production by PMELs in
the presence of simvastatin, we supplemented simvastatin-
treated PMEL cultures with 1 mM mevalonate or vehicle
control. We found that mevalonate rescued both prolife-
ration and IFN-g production by PMELs, suggesting that direct
inhibition of the HMG-CoA reductase pathway, rather than an
Thy 1.1
CD
8
3 Doses1 DoseVehicle
0.78% 0.01%0.03%
Tail dermisTail epidermis
Ear dermisEar epidermis
0
1,000
2,000
3,000
4,000
5,000
N
o.
 o
f P
M
EL
/1
06
si
ng
le
t c
el
ls 
P=0.043
Ve
hic
le
3 D
os
es
 IF
N-
γ
Ve
hic
le
1 D
os
e
3 D
os
es
0
50
100
150
N
o.
 o
f P
M
EL
/1
05
CD
45
+
 
ce
lls
NS
P=0.02
Ve
hic
le
1 D
os
e
3 D
os
es
 0
50
100
150
N
o.
 o
f P
M
EL
/1
05
CD
45
+
 
ce
lls
 
NS
Ve
hic
le
1 D
os
e
3 D
os
es
 0
1,000
2,000
3,000
4,000
N
o.
 o
f P
M
EL
/1
05
CD
45
+
 
ce
lls
NS
Ve
hic
le
1 D
os
e
3 D
os
es
 0
100
200
300
400
500
N
o.
 o
f P
M
EL
/1
05
CD
45
+
 
ce
lls
NS
Ve
hic
le
1 D
os
e
3 D
os
es
 0
200
400
600
800
1,000
N
o.
 o
f P
M
EL
/1
05
CD
45
+
 
ce
lls
 
NS
Ve
hic
le
1 D
os
e
3 D
os
es
0
100
200
300
N
o.
 o
f P
M
EL
/1
05
CD
45
+
 
ce
lls
NS
Ve
hic
le
1 D
os
e
3 D
os
es
 0.25
0.5
1
2
4
8
16
32
64
CX
CL
10
R
el
at
iv
e 
fo
ld
 e
xp
re
ss
io
n
NS
LN
Spleen
Figure 3. Acute treatment with simvastatin reduces T-cell numbers in the epidermis. Vitiligo was induced and mice were treated with one dose or three
daily doses of simvastatin (0.8mg) or vehicle control 5 weeks after vitiligo induction. (a) Representative flow plots show a reduced number of melanocyte-specific
CD8þT cells (PMELs) in the ear epidermis of the mice that received one or three daily doses of simvastatin when compared with vehicle. (b) The effects
of acute treatment with simvastatin on the total number of PMELs on ear skin, tail skin, lymph nodes (LNs), and spleen. NS, not significant. (c) Neutralization of
IFN-g has a similar effect on ear skin. (d) The relative expression of CXCL10 was unaffected in the ear skin of mice treated with one or three daily doses of
simvastatin.
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off-target effect, was responsible for reduced proliferation and
function of PMELs in the presence of simvastatin (Figure 4c–f).
Simvastatin reverses established vitiligo
Because simvastatin prevented depigmentation in our mouse
model and directly reduced the numbers of PMELs in the skin
in vivo as well as the function of PMELs in vitro, we tested
whether simvastatin could also reverse established depigmen-
tation in our mouse model of vitiligo. Mice were induced with
vitiligo as above and allowed to depigment and then stabilize
for 10 to 12 weeks. Those with 450% depigmentation on
their tails were randomized into two treatment groups, either
with simvastatin 0.8 mg three times weekly or vehicle control
for a total of 4 to 6 weeks. Photographs of the tails before and
after treatment were analyzed using ImageJ to calculate the
percent pigmentation of the tail, and therefore the degree of
repigmentation, after treatment. Despite no effect on the total
number of melanocyte-specific CD8þ T cells present in the
skin, we found that there was a significant increase in
pigmentation in the group treated with simvastatin compared
with the control group, as evidenced by the newly appearing
macules of pigment around the hair follicles (Figure 5a–d),
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providing a rationale for clinical studies in humans to test
simvastatin as a potential treatment for vitiligo.
DISCUSSION
Here we report the ability of simvastatin to both prevent and
reverse established depigmentation in a mouse model of
vitiligo. This is consistent with previous observations that the
IFN-g signaling pathway is critical for both the progression and
maintenance of depigmentation in our mouse model (Harris
et al., 2012), that STAT1 activation is required for IFN-g
signaling (Aaronson and Horvath, 2002), that simvastatin
inhibits IFN-g-induced STAT1 activation in vitro (Li et al.,
2011; Zhao et al., 2011), and that simvastatin reversed
depigmentation in a patient with vitiligo (Noel et al., 2004).
We hypothesized that the mechanism of action of simvastatin
in vitiligo was to inhibit IFN-g-induced CXCL10 production in
the skin, and therefore interfere with proper homing of
autoreactive T cells to the epidermis. However, despite its
clear efficacy in our mouse model of vitiligo, its mechanism of
action does not appear to be straightforward. This is consistent
with multiple previous studies showing pleiotropic effects of
statins on various T cell–mediated autoimmune diseases
(Greenwood et al., 2006).
Simvastatin did indeed prevent the migration of melano-
cyte-specific CD8þT cells to the skin during vitiligo progres-
sion while not decreasing their viability, as their numbers were
unaffected in skin-draining lymph nodes, spleen, and blood.
These effects are similar to what we observed in our model
when we neutralized IFN-g (Harris et al., 2012). Short-term
treatment with simvastatin reduced the number of PMELs
within the ear epidermis but not tail, and this may be because
of the difference in their thickness. The epidermis of the tail is
thick, whereas the epidermis of the ear is thinner. CD8þ T
cells, which drive melanocyte destruction in humans and our
mouse model, have been reported to express adhesion
molecules upon entry into the epidermis that helps to retain
them there. One possibility is that the thicker epidermis of the
tail with more adhesion molecules is better able to retain the
PMELs than that of the thinner ear epidermis. Alternatively,
simvastatin may have better penetration of the thinner
epidermis of the ear compared with the tail, although high
lipophilicity of simvastatin makes this less likely.
Despite the ability of simvastatin to reduce the number of
PMELs in the epidermis, we found that CXCL10 expression
was not reduced in the skin after short-term treatment,
suggesting that this effect of simvastatin was independent of
CXCL10. We then found that simvastatin reduced T-cell
proliferation and IFN-g production in vitro. This is consistent
with a study that reported decreased superantigen-induced
IFN-g production by human CD4þ T cells ex vivo isolated
from subjects treated with simvastatin compared with their
responses before treatment (Fehr et al., 2004), suggesting
that it has additional effects on T cells. STAT1 is also
phosphorylated by IL-12 (Schroder et al., 2004), a cytokine
that induces IFN-g production, and certain STAT1 mutations
in humans result in decreased IFN-g production after IL-12
stimulation (van de Veerdonk et al., 2011), suggesting that
STAT1 inhibition by simvastatin may have effects upstream of
IFN-g production as well. Alternatively, inhibition of HMG-
CoA reductase may affect signaling mediators other than
STAT1 that are required for T-cell proliferation and/or IFN-g
production. Interestingly, despite reversing vitiligo, simvastatin
did not affect the number of PMELs in the skin in
established disease, suggesting that simvastatin applies this
effect primarily by mechanisms other than recruitment of
autoreactive T cells. Previous studies have shown that statins
could have multiple additional effects on T cells, in addition to
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Figure 5. Simvastatin reverses established vitiligo. Mice with extensive
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or vehicle control three times weekly beginning 12 weeks after vitiligo
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percent tail pigmentation only in mice treated with simvastatin. (d) A
representative tail from each group before and after treatment is shown.
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their ability to influence T-cell recruitment and proliferation.
Consistent with this, we found a direct effect on IFN-g
production after stimulation in vitro, and thus hypothesize
that simvastatin inhibits the activation or effector status of
PMELs that remain in the skin to promote repigmentation.
Further experiments are needed to elucidate the exact
mechanisms by which simvastatin acts to reverse vitiligo in
our mouse model.
The dose of simvastatin used for our in vivo studies in mice
(up to 40 mg kg 1) is much higher than what is used in
humans (up to 80 mg day1, B1 mg kg1). However, high
doses are required for treatment of rodents because of their
rapid upregulation of HMG-CoA reductase in response to
treatment with statins (Kita et al., 1980). The optimal dose we
identified in our mouse model is consistent with established
active doses in rodents (Mundy et al., 1999; Dimmeler et al.,
2001; Ni et al., 2001), as well as doses tested in a mouse
model of rheumatoid arthritis (Leung et al., 2003). Notably,
the one vitiligo patient who reportedly responded to sim-
vastatin clinically was on the highest FDA-approved dose of
simvastatin, 80 mg per day (Noel et al., 2004).
Statins are metabolized and concentrate in the liver, result-
ing in low levels circulating in the plasma and through tissues
(Stamm and Ornstein, 2005). Therefore, high doses may be
required for efficacy in humans if the target tissue is the skin or
blood. However, the 80 mg dose of simvastatin increases the
risk of myopathy and rhabdomyolysis that led to removal of
this dose by the FDA (Desai et al., 2014). Whether simvastatin
will be required for successful treatment of vitiligo patients, or
whether other statins with fewer side effects could be effective,
is unknown. Simvastatin is highly lipophilic (Stamm and
Ornstein, 2005), and this may promote its accumulation in
multiple tissues other than the liver, including the skin. This
may contribute to its therapeutic effects in vitiligo, and may
also explain why it has more side effects. Future studies in
humans may consider testing simvastatin in a topical formu-
lation, as this should result in fewer side effects, and topical
simvastatin was reported to reduce inflammation in a mouse
model of irritant dermatitis (Otuki et al., 2006).
Simvastatin is an inexpensive, relatively safe FDA-approved
medication that prevents and reverses depigmentation in our
vitiligo mouse model, and it reversed depigmentation in one
reported vitiligo patient (Noel et al., 2004). Its use may be
repurposed to provide the first systemic treatment option for
patients with vitiligo, and could also be reformulated as a
topical treatment option. Based on these observations, a
clinical trial in a small number of patients with high-dose
simvastatin would be useful to determine whether larger
studies to prove efficacy would be a worthwhile investment.
MATERIALS AND METHODS
Mice
KRT14-Kitl*4XTG2Bjl (Krt14-Kitl*) mice were a gift from BJ Longley
(University of Wisconsin, Madison, WI). Thy1.1þ PMEL TCR-trans-
genic mice were obtained from The Jackson Laboratory (Bar Harbor,
ME; stock no. 005023, B6.Cg Thy1a/CyTg(TcraTcrb)8Rest/J). All mice
were on a C57BL/6J background, were maintained in pathogen-free
facilities at the University of Massachusetts Medical School, and
procedures were approved by the University of Massachusetts
Medical School Institutional Animal Care and Use Committee.
Simvastatin preparation
Simvastatin (Sigma-Aldrich, St Louis, MO) was activated before use as
described previously (Sadeghi et al., 2000). Briefly, 12 mg of
simvastatin was dissolved in 300ml of ethanol and then 450ml of
0.1 N NaOH was added to the solution and subsequently incubated
at 50 1C for 2 hours. The pH was then brought to 7.0 by adding HCl,
and the final concentration of the stock solution was adjusted to
4 mg ml 1 and kept at 4 1C.
Induction of vitiligo and treatment of mice
Vitiligo was induced through adoptive transfer of PMEL CD8þ T cells
as described previously (Harris et al., 2012). Briefly, PMEL CD8þ
T cells were isolated from the spleens of PMEL TCR-transgenic mice
through negative selection on microbeads (Miltenyi Biotec, Auburn,
CA) according to the manufacturer’s instructions. Purified CD8þ
T cells (1 106) were injected intravenously into sublethally
irradiated (500 rad 1 day before transfer) Krt14-Kitl* hosts (12 to
16 weeks of age). Recipient mice also received intraperitoneal
injection of 1 106 plaque-forming units of rVV-hPMEL (N Restifo,
National Cancer Institute, NIH, Bethesda, MD) on the same day of
transfer. Treatment with simvastatin to prevent vitiligo was performed
by i.p. injection of the drug three times weekly for the duration of 5
weeks. Control mice received either no treatment or were treated
with an equal volume of phosphate-buffered saline. Vitiligo score was
objectively quantified by an observer blinded to the experimental
groups, using a point scale based on the extent of depigmentation at
four easily visible locations, including the ears, nose, rear footpads,
and tails as described previously (Harris et al., 2012). Each location
was examined, and the extent of depigmentation was estimated as a
percentage of the anatomic site; both left and right ears and
left and right rear footpads were estimated together and therefore
evaluated as single sites. Points were awarded as follows:
no evidence of depigmentation (0%) received a score of 0, 40 to
10%¼ 1 point, 410 to 25%¼ 2 points, 425 to 75%¼ 3 points,475
too100%¼ 4 points, and 100%¼ 5 points. The ‘‘vitiligo score’’ was
the sum of the scores at all four sites, with a maximum score of
20 points. Acute treatment with simvastatin was performed by i.p.
injection of either 1 dose or 3 daily doses of simvastatin (0.8 mg)
5 weeks after vitiligo induction, or vehicle control. Acute IFN-g
blockade was through i.p. injection of 3 daily doses of IFN-g–
neutralizing antibody (500mg, XMG-6) or vehicle control.
To induce repigmentation, 10 to 12 weeks after induction of
vitiligo, mice with at least 50% tail depigmentation were randomly
assigned to receive either 0.8 mg of simvastatin as before or vehicle
control for a total of 4 to 6 weeks. Treatment efficacy was objectively
quantified by comparison of the tail photographs before and after
treatment with ImageJ software (NIH, Bethesda, MD). Briefly, all
images were converted to 8-bit black and white, and the brightness
threshold adjusted to 100, converting all pigmented areas to black
and all depigmented areas to white. The outline of the tail was
selected, and the mean area over threshold calculated, representing
the fraction of pigmented tail skin. This was multiplied by 100,
converting the fraction to percent pigmentation of the tail. Percent
change over baseline reflects the percent pigmentation after treatment
minus the percent pigmentation before treatment and, therefore, a
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positive number reflects percent repigmentation whereas a negative
number reflects further depigmentation.
In vitro T-cell proliferation and cytokine production assays
TCR-transgenic CD8þ T cells that recognize premelanosome protein
(PMEL) were isolated from the spleens of transgenic mice using a
MACS CD8-negative isolation kit (Miltenyi Biotec, Auburn, CA) as
mentioned above. Isolated CD8þ T cells were suspended at
1.0 107 cells per ml in 2 mM carboxyfluorescein succinimidyl ester
(Invitrogen, Carlsbad, CA) in phosphate-buffered saline with 0.1%
fetal bovine serum and incubated for 10 minutes at 37 1C. Subse-
quently, cold fetal bovine serum was added at an equal volume, the
cells were centrifuged at 350 g, and resuspended in T-cell media
(RPMI-1640 Gibco (Life Technologies, Grand Island, NY), 10% fetal
bovine serum, 2 mM glutamax, 1 mM sodium pyruvate, 10 mM HEPES,
0.5 nonessential amino acids, and 50mM b-Mercaptoethanol).
5.0 104 cells per well were incubated in a 96-well plate for
72 hours at 37 1C. Wells in a 96-well plate were previously coated
overnight with 3mg ml 1 CD3 antibody in phosphate-buffered saline
at 4 1C. Stimulated cells were incubated in the presence of 2mg ml 1
of soluble CD28 antibody and unstimulated cells were incubated in
uncoated wells. Cells were also incubated with simvastatin or both
simvastatin and 1 mM (S)-Mevalonic Acid Lithium Salt (Sigma-Aldrich).
Surface staining for flow cytometry was then performed for CD45
(clone 30-F11; BioLegend, San Diego, CA), CD8b (BioLegend clone
YTS1560707), Thy1.1 (BioLegend clone OX-7), and intracellular
staining was performed for IFN-g (clone XMG1.2; ebioscience, San
Diego, CA). Data were pooled from three separate experiments, and
the average numbers from untreated groups (neither simvastatin nor
mevalonate) were used for normalization.
Flow cytometry
Ears, tails, spleens, and skin-draining lymph nodes were harvested at
the indicated times. Spleens were disrupted, and the red blood cells
were lysed with red blood cell lysis buffer (Life Technologies). Ear and
tail skin were incubated in skin digest medium (RPMI containing
0.5% deoxyribonuclease (DNase) I (Sigma-Aldrich) and liberase TL
enzyme blend (0.5 mg ml 1) (Roche, Indianapolis, IN)) and pro-
cessed with a medimachine (BD Biosciences, San Jose, CA) as
described previously (Harris et al., 2012). For separation of the
dermis and epidermis, tail skin samples were incubated with
dispase (2.4 U ml 1; Roche) for 1 hour at 37 1C. Epidermis was
removed and mechanically disrupted with 70mm cell strainers, and
dermis samples were incubated with collagenase IV (1 mg ml 1) with
DNase I (0.5 mg ml 1; Sigma-Aldrich) for 1 hour at 37 1C on a shaker.
Cells were filtered through a 70-mm mesh before analysis. The
following antibodies were obtained from BioLegend: mouse (CD8b,
CD45.2, CD90.1, and Fc block). The data were collected and
analyzed with a BD LSR II flow cytometer (BD Biosciences) and
FlowJo (Tree Star, Ashland, OR).
Quantitative real-time RT–PCR
The expression of CXCL10 in mouse tissues was performed using
quantitative real-time RT–PCR. Ear and tail skin from three control
and three simvastatin-treated mice were analyzed in each experi-
ment. The tissues obtained were stored at  80 1C until RNA was
extracted using the RNeasy Plus Mini Kit (Qiagen, Valencia, CA)
according to the manufacturer’s instructions. Complimentary DNA
was generated with iScript complimentary DNA synthesis kit
(Bio-Rad, Hercules, CA). Real-time PCR was conducted with com-
plimentary DNA and iQ SYBR Green (Bio-Rad) in a Bio-Rad iCycler
iQ according to the manufacturer recommendations. Mouse primer
sequences are as follows: Cxcl10 50-AGGGGAGTGATGGAG
AGAGG-30 (sense) and 50-TGAAAGCGTTTAGCCAAAAAAGG-30
(antisense); actin-b (Actb): 50-GGCTGTATTCCCCTCCATCG-30 (sense)
and 50-CCAGTTGGTAACAATGCCATGT-30 (antisense). CXCL10
expression is reported after normalization to expression of ACTB.
Data were pooled from three separate experiments and gene expres-
sion is reported relative to the lowest expression in untreated mice
within each experiment after normalization to expression of b-actin.
Statistical analysis
Statistical analysis was performed using Prism software (GraphPad
Software, La Jolla, CA). Dual comparisons were made using
the paired or unpaired Student’s t-test when applicable. Groups of
Z3 were analyzed by analysis of variance with Dunnett’s post-tests.
P-values of o0.05 were considered significant.
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